Biohaven Pharmaceutical said on May 23 the company’s experimental drug for patients with spinocerebellar ataxia, a genetic disease that affects the nervous system, failed to meet the main goal of a late-stage study.
As the fairness of orphan drug exclusivities is debated in Congress, the U.S. Food and Drug Administration granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences.
Eisai, Biogen take another step toward potential approval of Alzheimer’s drugAlzheimer's, Alzheimer's Disease, Alzheimer's Diseases, Alzheimer’s, Alzheimer’s Disease, Alzheimer’s disease, Alzheimer’s disease, Amyloid Beta, Biogen, Biologics License Application (BLA), CNS Disorders, Dementia, Eisai, Neurodegenerative Diseases, Neurodegenerative Disorders, Neuroscience, Priority Review, R&D
Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.
Parkinson’s Foundation Announces Major Expansion of PD GENEration Study, Increasing Access to Genetic Testing and Counseling Across the U.S.CNS Disorders, Gene Testing, Genetic Testing, Genomic Tests, Neurodegenerative Disorders, Parkinson's, Parkinson's Disease, Parkinson's Disease, Parkinson's Disease, Parkinson’s disease, Parkinson’s disease, Parkinson’s disease, Parkinson’s Disease, Personalization, Personalized Care, Personalized health, Personalized Medicine, Personalized Therapeutics
The Parkinson’s Foundation has announced the expansion of PD GENEration: Mapping the Future of Parkinson’s Disease, a first-of-its-kind national initiative offering genetic testing and counseling for people with Parkinson’s disease (PD) at no cost.
Cassava Sciences hits back at NYT for alleged “pre-set narrative”Alzheimer's Diseases, Alzheimer’s, Alzheimer’s Disease, Alzheimer’s disease, Alzheimer’s disease, Brain Diseases, Centers for Medicare & Medicaid Services, CNS Disorders, Dementia, Early Alzheimer's Disease, Early Alzheimer’s, Financing, Neurodegenerative Disorders, Neuroscience, New York Times, Newspapers, Papers, R&D, R&D, Research Papers, Scientific Papers, Series A
Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.
Biogen Inc. decided to withdraw the marketing authorization application for the company’s troubled Alzheimer’s drug aducanumab in Europe after failing to convince the regulator of the product’s benefits.
Satellite Bio launched Wednesday with $110 million in previously undisclosed Seed and Series A investments led by aMoon Growth.
AbbVie terminated the company’s collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement disorders.
PTC Therapeutics Inc. announced that the company completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency (PTC-AADC) with the Committee for Advanced Therapies (CAT).
U.S. Medicare limits coverage for Biogen’s Alzheimer’s drugAlzheimer's Disease, Alzheimer’s, Alzheimer’s Disease, Alzheimer’s disease, Amyloid Beta, Amyloid Plaques, Biogen, Centers for Medicare & Medicaid Services, CNS Disorders, Dementia, Early Alzheimer's Disease, Neurodegenerative Diseases, Plaque, Protein Plaques, Therapeutics
U.S. Medicare limits coverage for Biogen’s Alzheimer’s drug Published April 7, 2022; 7:40 PM EDT By Deena Beasley April 7 (Reuters) – The U.S. government health plan for people age […]